Helmholtz

Top scientists and companies will meet in Berlin-Buch for the 2025 Helmholtz Drug Discovery Conference from April 28-30 to discuss RNA drugs, PROTACs, AI in drug discovery, and chemoproteomics and to form new collaborations.

The Helmholtz Institute for Translational AngioCardioScience (HI-TAC) invites attendees to its first Symposium on April 28 and 29, 2025. Researchers from around the world will meet at Heidelberg University to discuss how the heart and blood vessels communicate with the rest of the body to shape health.

The Helmholtz Association is pooling its commitment to prevention research with the launch of the Helmholtz Health Prevention Task Force. In a strategy paper published in “Nature Medicine,“ the committee outlines initial concepts for integrating prevention more effectively into medical practice.

How can AI transform scientific research? The Helmholtz Foundation Model Initiative brought together a diverse group of experts during its first workshop. In an interview, Max Delbrück Center scientist Dagmar Kainmüller explains foundation models and why interdisciplinary collaboration is important.

Helmholtz invests €18 million in AI innovation ecosystems: Nine Helmholtz centers open their High-Performance Computing infrastructure to companies and connect businesses with their AI experts. More than €2 million will go to the Max Delbrück Center.

Caroline Schweiger-Eisbacher is the new Scientific Advisor to the Vice President of Helmholtz Health, Maike Sander. In this role, Schweiger-Eisbacher helps facilitate collaboration and communication across the Helmholtz Health network.

Maike Sander, Scientific Director of the Max Delbrück Center, has been elected Vice President of Helmholtz Health. In this pivotal role, she will drive collaboration among leading biomedical research centers and advance the field of preventative precision medicine over the next two years.

As Scientific Director of Max Delbrück Center, Maike Sander is driving a bold shift toward interdisciplinary research to address the health challenges of our time. As a diabetes researcher, her next frontier is to use organ-on-a-chip technologies to build more accurate models of the human pancreas.

Foundation models are complex AI applications with enormous potential. Trained on vast datasets from medicine, climate, or material science, they can uncover new relationships and make predictions. Helmholtz is supporting this pioneering work, with €5.55 million going to the Max Delbrück Center.

What opportunities lie ahead for the future of medical research and healthcare? Scientists from the Helmholtz Association share their ideas with decision-makers from science, politics, patient organizations, biotech, and the pharmaceutical industry at the first Helmholtz Health Summit in Berlin.